Part III. Neuropathology of Alzheimer's disease

Disease-a-Month

Volumn 46, Issue 10, 2000, Pages 688-706

  Arnold, Steven E ^a,b  

^a Fellow Institute On Aging   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; AUTOPSY; BRAIN ATROPHY; CEREBROVASCULAR DISEASE; DENDRITE; HUMAN; INFLAMMATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SENILE PLAQUE; SYNAPSE;

EID: 85058248481     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(00)90030-0     Document Type: Review

References (79)

1. Uber eine eigenartige erkrankung der hirnrinde
2. Reappraisal of the fine structure of Alzheimer's neurofibrillary tangles
3. Image reconstruction of the Alzheimer paired helical filament
4. A68: A major subunit of paired helical filaments and derivatized forms of normal tau
5. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms
6. The neurofibrillary pathology of Alzheimer's disease
7. Ultrastructural studies in Alzheimer's presenile dementia
8. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
9. Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques
10. Alzheimer's disease: A double-labeling immunohistochemical study of senile plaques
11. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
12. Plaque-associated neuronal proteins: A recurrent motif in neuritic amyloid deposits throughout diverse cortical areas of the Alzheimer's disease brain
13. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
14. Alzheimer patients: Preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system
15. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques
16. Intracellular APP processing and A beta production in Alzheimer disease
17. Processing of the amyloid-b protein precursor
18. The pathogenesis of senile plaques
19. Translating cell biology into therapeutic advances in Alzheimer's disease
20. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease
21. Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation
22. Perforant pathway changes and the memory impairment of Alzheimer's disease
23. Neuropathological staging of Alzheimer-related changes
24. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: A quantitative evaluation of a one-year autopsy population from a geriatric hospital
25. Determinants of neuronal vulnerability in neurodegenerative diseases
26. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype
27. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
28. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older
29. Neuritic pathology and dementia in Alzheimer's disease
30. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution
31. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease
32. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
33. Diagnosis of Alzheimer's disease
34. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease
35. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease
36. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
37. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
38. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease
39. Multivariate analysis of laminar patterns of neurodegeneration in posterior cingulate cortex in Alzheimer's disease
40. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis
41. Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: Relationship to disease pathogenesis
42. Increased nuclear DNA oxidation in the brain in Alzheimer's disease
43. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo
44. Protein oxidation in aging brain
45. Advanced glycation end products contribute to amyloidosis in Alzheimer disease
46. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay
47. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ
48. Dendritic changes in Alzheimer's disease and factors that may underlie these changes
49. Massive somatodendritic sprouting of cortical neurons in Alzheimer's disease
50. Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer's disease
51. Microtubular reorganization and dendritic growth response in Alzheimer's disease
52. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cogntive impairment
53. Correlations of synaptic and pathological markers with cognition of the elderly
54. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease
55. Quantitative assessment of synaptic density in the outer molecular layer of the hippocampal dentate gyms in Alzheimer's disease
56. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia
57. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system
58. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
59. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex
60. Brain inflammation in Alzheimer disease and the therapeutic implications
61. Overlap between pathology of Alzheimer disease and vascular dementia
62. Vascular factors and Alzheimer disease
63. Differences between vascular and plaque core amyloid in Alzheimer's disease
64. Cerebral amyloid angiopathy in dementia and old age
65. Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease
66. Brain microvascular changes in Alzheimer's disease and other dementias
67. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
68. Selective loss of central cholinergic neurons in Alzheimer's disease
69. Enzyme histochemical studies of senile plaques
70. A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease
71. Alzheimer's disease: A correlative study
72. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication
73. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease: A hypothesis
74. Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease
75. Clinical and neuropathological correlates of depression in Alzheimer's disease
76. Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential
77. Neuropeptides and Alzheimer's disease pathology
78. Neuropeptides and Alzheimer's disease